A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells

Volume: 5, Issue: 6, Pages: e1151592 - e1151592
Published: Mar 10, 2016
Abstract
Ibrutinib, a BTK inhibitor, is currently used to treat various hematological malignancies. We evaluated whether ibrutinib treatment during development of murine bone marrow-derived dendritic cells (DCs) modulates their maturation and activation. Ibrutinib treatment increased the proportion of CD11c(+) DCs, upregulated the expression of MHC-II and CD80 and downregulated Ly6C expression by DCs. Additionally, ibrutinib treatment led to an increase...
Paper Details
Title
A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
Published Date
Mar 10, 2016
Volume
5
Issue
6
Pages
e1151592 - e1151592
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.